MXPA04003278A - Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina. - Google Patents

Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina.

Info

Publication number
MXPA04003278A
MXPA04003278A MXPA04003278A MXPA04003278A MXPA04003278A MX PA04003278 A MXPA04003278 A MX PA04003278A MX PA04003278 A MXPA04003278 A MX PA04003278A MX PA04003278 A MXPA04003278 A MX PA04003278A MX PA04003278 A MXPA04003278 A MX PA04003278A
Authority
MX
Mexico
Prior art keywords
triazolo
methoxy
aryl
receptor antagonists
adenosine receptor
Prior art date
Application number
MXPA04003278A
Other languages
English (en)
Spanish (es)
Inventor
Schmitt Sebastien
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA04003278A publication Critical patent/MXPA04003278A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MXPA04003278A 2001-10-08 2002-09-28 Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina. MXPA04003278A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01123949 2001-10-08
PCT/EP2002/010917 WO2003031445A1 (en) 2001-10-08 2002-09-28 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
MXPA04003278A true MXPA04003278A (es) 2004-07-23

Family

ID=8178877

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003278A MXPA04003278A (es) 2001-10-08 2002-09-28 Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina.

Country Status (16)

Country Link
US (1) US6693116B2 (OSRAM)
EP (1) EP1436292B1 (OSRAM)
JP (1) JP4101756B2 (OSRAM)
KR (1) KR100604407B1 (OSRAM)
CN (1) CN1254475C (OSRAM)
AR (1) AR036735A1 (OSRAM)
AT (1) ATE338043T1 (OSRAM)
AU (1) AU2002338827B2 (OSRAM)
BR (1) BR0213177A (OSRAM)
CA (1) CA2462801A1 (OSRAM)
DE (1) DE60214408T2 (OSRAM)
ES (1) ES2269772T3 (OSRAM)
MX (1) MXPA04003278A (OSRAM)
PL (1) PL370565A1 (OSRAM)
RU (1) RU2298009C2 (OSRAM)
WO (1) WO2003031445A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1830978B (zh) * 2005-03-07 2010-06-16 中国人民解放军军事医学科学院毒物药物研究所 吡唑并[4,3-c]喹啉-3-酮化合物、其制备方法及其应用
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2727036C (en) * 2008-06-20 2017-03-21 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
EP2296475A4 (en) 2008-06-20 2014-03-05 Genentech Inc TRIAZOLOPYRIDINE COMPOUNDS JAK KINASE INHIBITORS AND METHODS
SG172206A1 (en) * 2008-12-19 2011-07-28 Leo Pharma As Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
BRPI1009637A2 (pt) 2009-06-05 2019-04-30 Cephalon, Inc composto, composição e uso de um composto
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
IN2015DN00202A (OSRAM) * 2012-07-12 2015-06-12 Chiesi Farma Spa
CN104768954B (zh) * 2012-09-14 2017-11-17 美国陶氏益农公司 由4‑氨基‑2,5‑二甲氧基嘧啶制备2‑氨基‑5,8‑二甲氧基[1,2,4]三唑并[1,5‑c]嘧啶的改善方法
PE20161323A1 (es) 2013-09-05 2016-11-25 Hoffmann La Roche Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE287262C (OSRAM) *
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives

Also Published As

Publication number Publication date
CN1254475C (zh) 2006-05-03
PL370565A1 (en) 2005-05-30
RU2298009C2 (ru) 2007-04-27
AR036735A1 (es) 2004-09-29
BR0213177A (pt) 2004-09-14
CA2462801A1 (en) 2003-04-17
EP1436292A1 (en) 2004-07-14
WO2003031445A1 (en) 2003-04-17
ES2269772T3 (es) 2007-04-01
AU2002338827B2 (en) 2007-09-06
ATE338043T1 (de) 2006-09-15
KR100604407B1 (ko) 2006-07-25
DE60214408D1 (de) 2006-10-12
US6693116B2 (en) 2004-02-17
JP4101756B2 (ja) 2008-06-18
JP2005508954A (ja) 2005-04-07
RU2004114277A (ru) 2006-01-10
KR20040044196A (ko) 2004-05-27
CN1564821A (zh) 2005-01-12
DE60214408T2 (de) 2007-03-08
US20030134873A1 (en) 2003-07-17
EP1436292B1 (en) 2006-08-30

Similar Documents

Publication Publication Date Title
HUP0102084A2 (hu) Kinolinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
PL373414A1 (en) 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
WO2003080580A3 (en) Quinoline derivatives and their use as 5-ht6 ligands
WO2003106428A8 (fr) Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine
BG103785A (en) Pyrrolo[2,3-d]pyrimidines and their application as tyrosine kinase inhibitors
BG104248A (en) Benzamidoxim derivatives, intermediate products and methods for preparing and using them as fungicides
NZ512731A (en) Tricyclic inhibitors of poly(ADP-ribose) polymerases
CA2286723A1 (en) Tricyclic compounds
DE60039359D1 (de) Amide als pyruvatdehydrogenaseinhibitoren
DE60236719D1 (de) Purinderivate als antagonisten an purinergen rezeptoren
MXPA04003278A (es) Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina.
MX2012008147A (es) Derivados de pirrazolopiridina.
MX2007004250A (es) Derivados de imidazo[1,5-a]triazolo[1,5-d]benzodiazepina para el tratamiento de trastornos cognitivos.
NZ519126A (en) Novel IL-8 receptor antagonists
MXPA02011464A (es) Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1.
ATE337827T1 (de) N-aryl-4,5-diaminopyrazole und diese verbindungen enthaltende färbemittel
HUP0101311A1 (hu) 3-Szubsztituált 3,4,5,7-tetrahidro-pirrolo[3',4':4,5]tieno[2,3-d]pirimidin-származékok, eljárás előállításukra és alkalmazásuk 5-HT antagonistákként
HK1049486A1 (zh) 作為mcp-1受體拮抗劑的吲類衍生物
AR021094A1 (es) Compuestos heterociclicos inhibidores de la fosfodiesterasa iv y su uso para el tratamiento de enfermedades inflamatorias
HU0103912D0 (en) Use of substituted alkylpyridazinone derivatives for the preparation of pharmaceutical compositions with anxiolytic activity
IS7152A (is) Glýsín-setin þíeno[2,3-d]pýrimidín með sameinaða LH og FSH gerandefnisvirkni
ATE238300T1 (de) (3,4-dihydro-2h-benzo(1,4)oxazinyl-methyl)-3-(1 - indol-3-yl)-alkylamine
AU2003260569A1 (en) Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics
NO308304B1 (no) Nye 5H-thiazol[3,2-a]pyrimidin-5-on derivater, anvendelse derav for fremstilling av farmasøytiske sammensetninger, farmasøytiske sammensetninger inneholdende derivatene, samt et preparat til behandling av psykose, schizofreni og angst
MY138045A (en) New benzo[b]pyrano[3,2-h]acridin-7-one cinnamate compounds, a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FG Grant or registration